Islet cell transplantation represents a transformative therapy for patients with type 1 diabetes and severe hypoglycemia unawareness. By infusing donor-derived insulin-producing islets into the liver, the procedure can restore endogenous insulin secretion and improve glycemic control. Yet despite decades of refinement, immune-mediated rejection remains the most substantial barrier to long-term success. Even with current immunosuppressive protocols, many grafts fail within five years. The challenge is multifactorial: alloreactive T cells and antibodies attack the donor islets, recurrent autoimmunity erodes beta cells, and the harsh hepatic microenvironment contributes to early islet loss. This article explores the most promising innovative approaches to reduce rejection in islet cell transplantation, from advanced immunosuppression and encapsulation to genetic engineering and immune tolerance induction. It also examines how combining these strategies with stem cell–derived islets and real-time immune monitoring could fundamentally change the outlook for cellular replacement therapy in diabetes.

The Rejection Problem: Why Islet Grafts Fail

To appreciate the innovations, one must first understand the immunological challenges. Islet cells from a deceased donor express foreign human leukocyte antigens (HLA) that are immediately recognized by the recipient’s immune system. Both the innate and adaptive arms mount aggressive responses. Macrophages and dendritic cells engulf islet debris and present donor antigens to T cells, while B cells produce donor-specific antibodies. The resulting inflammatory cascade destroys the fragile islets within days to weeks, a phenomenon known as early graft loss. Chronic rejection, driven by memory T cells and alloantibodies, further erodes function over months and years.

Beyond alloreactivity, patients with type 1 diabetes harbor pre-existing autoreactive T cells directed at beta-cell antigens. These cells can be reactivated after transplantation, contributing to graft destruction even when HLA matching is optimized. The portal vein infusion site also poses mechanical and metabolic stresses: hypoxia, low oxygen tension (20–40 mmHg), and exposure to gut-derived endotoxins trigger an instant blood-mediated inflammatory reaction that destroys up to 50% of infused islets within hours.

Traditional immunosuppression—typically a combination of a calcineurin inhibitor, mycophenolate mofetil, and corticosteroids—partially controls these responses but at a cost. Nephrotoxicity, increased infection risk, and metabolic side effects are common. Moreover, these regimens are insufficient to prevent rejection in many patients, particularly when islet mass is marginal. This reality has spurred a wave of innovation aimed at making islet transplantation a more durable and widely accessible therapy.

Innovative Immunosuppressive Regimens

Newer immunosuppressive agents focus on selectivity and reduced toxicity. One of the most impactful developments is the use of T-cell costimulation blockade. Belatacept, a fusion protein that blocks CD80/CD86 interactions with CD28, has shown promise in kidney transplantation and is now being investigated for islet transplantation. By interfering with the second signal required for T-cell activation, belatacept can prevent alloimmune responses without the nephrotoxicity of calcineurin inhibitors. Early-phase trials report improved glycemic control and reduced rejection rates when belatacept is combined with sirolimus and low-dose tacrolimus.

Targeted Biologics and Induction Therapy

Monoclonal antibodies directed against specific immune cells are increasingly used as induction therapy. Alemtuzumab (anti-CD52) depletes T and B cells, providing a clean slate for islet engraftment. Rituximab (anti-CD20) depletes B cells to reduce antibody-mediated rejection. Basiliximab (anti-CD25) blocks the interleukin-2 receptor on activated T cells. Combinations of these agents, followed by maintenance therapy with sirolimus or mycophenolate, have improved early graft survival in clinical trials. The NICHE trial is currently comparing an alemtuzumab-based induction regimen with standard therapy in islet-alone recipients.

Janus Kinase Inhibitors

JAK inhibitors such as tofacitinib represent another frontier. These oral agents block cytokine signaling pathways critical for T-cell and NK-cell activation. Preclinical studies in nonhuman primate islet transplantation models have demonstrated prolonged graft survival with reduced side effects. Clinical translation is underway, and early results suggest these agents may replace or reduce the need for calcineurin inhibitors. A phase 2 study evaluating the JAK1/2 inhibitor ruxolitinib in combination with belatacept is expected to begin enrollment in late 2025.

Proteasome Inhibitors and Anti-Complement Therapy

Antibody-mediated rejection remains a major unsolved challenge. Bortezomib, a proteasome inhibitor, depletes plasma cells and reduces donor-specific antibody titers. Case reports in islet transplantation show reversal of acute antibody-mediated rejection when bortezomib is combined with plasmapheresis. Complement inhibition with eculizumab (anti-C5) is also being explored; a pilot study demonstrated that peri-transplant eculizumab reduced the need for exogenous insulin in sensitized recipients.

Encapsulation Technologies: Shielding Islets from Attack

Perhaps the most elegant strategy to avoid rejection is to physically separate donor islets from the immune system. Encapsulation involves surrounding islets with a semipermeable membrane that allows glucose and insulin to diffuse freely while excluding immune cells and antibodies. This approach could eliminate the need for systemic immunosuppression altogether.

Advances in biomaterials have been critical. Traditional alginate capsules trigger a foreign-body response characterized by macrophage accumulation and fibrosis. Newer materials, such as triazole-thiomorpholine dioxide alginate and zwitterionic hydrogels, resist protein adsorption and immune cell adhesion. Co-encapsulation of immunomodulatory molecules—interleukin-1 receptor antagonist, CTLA4-Ig, or regulatory cytokines—can create a locally tolerogenic microenvironment without systemic effects.

Macroencapsulation Devices

Macroencapsulation places a large number of islets within a single chamber. The most advanced device, the Beta-O2 Technologies macroencapsulation system, uses a planar membrane with an oxygen supply port. Clinical trials have shown that macroencapsulated human islets can survive and function for months, even in patients without immunosuppression. However, challenges remain with nutrient diffusion and fibrotic overgrowth. The OXYGENE-1 trial is currently evaluating a revised implantable oxygen delivery system to improve islet viability. Another approach is the ViaCyte PEC-Encap device, which uses a semipermeable pouch seeded with stem cell–derived pancreatic progenitors; while early results showed insulin production, device retrieval revealed limited engraftment due to foreign-body response.

Microencapsulation and Nanoencapsulation

Microencapsulation involves coating individual islets or small clusters with a hydrogel, typically alginate derived from seaweed. The material is biocompatible and can be chemically modified to reduce foreign body reactions. Recent advances include triazole-thiomorpholine dioxide alginate, which resists fibrotic overgrowth in nonhuman primates. Nanoencapsulation uses even thinner polymer layers, lowering the diffusion barrier and improving insulin kinetics. Groups at the Diabetes Research Institute have shown that an IL-1 receptor antagonist delivered via the capsule can locally suppress inflammation without systemic effects. Layer-by-layer nanocoating with polyelectrolytes (e.g., poly-L-lysine and alginate) allows precise control over capsule permeability and surface charge.

Conformal Coating

A newer method, conformal coating, uses droplet-based microfluidics to apply a thin, uniform polymer coating directly around each islet. This minimizes the capsule volume and improves oxygen exchange compared to traditional microcapsules. Preclinical data indicate that conformally coated islets can maintain normoglycemia in diabetic mice for over 200 days without immunosuppression. The approach is now moving toward large animal models. Microfluidic platforms that produce conformal coatings at high throughput are being developed for clinical-scale manufacturing.

Genetic Modification of Donor Cells

Rather than hiding islets from the immune system, genetic engineering can render them invisible or actively suppressive. Several strategies are under investigation, leveraging CRISPR/Cas9 and viral vector technologies.

Immune-Inhibitory Molecule Expression

Transducing donor islets with genes encoding immunomodulatory proteins can locally dampen the immune response. For example, expression of cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA4-Ig) blocks the CD28 costimulatory pathway. Expression of programmed death-ligand 1 (PD-L1) engages PD-1 on T cells to induce exhaustion. Transgenic pig islets expressing CTLA4-Ig have demonstrated extended survival in nonhuman primate transplant models. More recently, co-expression of PD-L1 and HLA-E (a nonclassical MHC molecule that inhibits NK cells) has been shown to protect human islet grafts from both T-cell and NK-cell attack in humanized mouse models.

Knockout of Xenoantigens

For xenotransplantation—using pig islets to overcome donor shortages—genetic editing of pigs is critical. CRISPR/Cas9 technology allows precise knockout of the α-galactosyltransferase gene that encodes the major xenoantigen targeted by human preformed antibodies. Further edits can add human complement regulatory proteins (CD46, CD55, CD59) to prevent complement-mediated lysis. The first clinical trial of genetically modified pig islets is anticipated soon, with the NIH-sponsored SONIC trial evaluating safety and efficacy in type 1 diabetes. Triple-knockout pigs (GGTA1, CMAH, B4GALNT2) combined with transgenic expression of human complement inhibitors have shown prolonged islet survival in nonhuman primates.

Inducing Local Immune Tolerance

Some researchers are engineering islets to secrete regulatory cytokines such as interleukin-10 or transforming growth factor-beta. These molecules promote regulatory T cell (Treg) expansion and shift the balance from effector to regulatory responses in the graft microenvironment. In rodent models, these engineered islets induce donor-specific tolerance, allowing subsequent unmodified grafts from the same donor to be accepted without immunosuppression. A novel approach uses CRISPR-mediated integration of IL-10 and PD-L1 transgenes into the AAVS1 safe harbor locus of stem cell–derived islets, creating a universal donor line that can evade immune detection.

HLA Engineering and Immune Evasion

Knocking out beta-2 microglobulin eliminates all HLA class I expression but renders islets vulnerable to NK cell lysis. A more refined strategy replaces endogenous HLA with HLA-E or HLA-G, which inhibit NK cells while maintaining some immune recognition. Alternatively, inserting “stealth” mutations in the peptide-binding groove of HLA can reduce alloreactive T-cell recognition without triggering NK attack. Preclinical studies with HLA-E–expressing insulin-producing cells show survival for over 100 days in immunocompetent mice.

Induction of Immune Tolerance: Teaching the Body to Accept

True immune tolerance—where the recipient’s immune system specifically does not attack the graft while remaining fully functional against pathogens—is the Holy Grail of transplantation. Several tolerance-inducing strategies are being tested in the context of islet transplantation.

Regulatory T Cell Therapy

Adoptive transfer of Tregs can suppress alloreactive T cells. Autologous Tregs are expanded ex vivo and infused around the time of transplantation. The ONE Study consortium has established safety protocols for Treg therapy in kidney transplantation, and islet-specific trials are underway. The Treg-Islet trial is evaluating combined Treg and low-dose immunosuppression in 18 patients with type 1 diabetes. A major challenge is ensuring sufficient Treg persistence and stability; engineering Tregs to express a chimeric antigen receptor (CAR-Treg) directed against donor HLA may enhance their homing and suppressive function at the graft site.

Mixed Hematopoietic Chimerism

By infusing donor bone marrow cells alongside donor islets, one can create a state of mixed chimerism. The donor hematopoietic stem cells co-engraft in the recipient’s bone marrow, leading to central deletion of donor-reactive T cells in the thymus. This approach has successfully induced tolerance in nonhuman primates and in a small number of patients undergoing kidney transplantation. The same principle is now being tested for islet transplantation at the University of Chicago and other centers. A conditioning regimen with low-dose total body irradiation and costimulatory blockade is used to permit chimerism while minimizing toxicity. Early results show sustained insulin independence in chimeric recipients without maintenance immunosuppression for over 2 years.

Tolerogenic Dendritic Cells and Antigen-Specific Therapy

Combining costimulatory blockade (e.g., belatacept) with infusion of tolerogenic dendritic cells can promote regulatory responses. These dendritic cells are treated ex vivo to express low levels of costimulatory molecules and high levels of PD-L1. When infused, they migrate to lymph nodes and present donor antigens in a nonactivating manner, converting naive T cells into Tregs. Early-phase trials have shown safety and preliminary evidence of immune modulation. An alternative antigen-specific approach uses co-transplant of donor apoptotic cells, which are taken up by recipient dendritic cells and induce a tolerogenic program that promotes Treg generation.

Challenges and Limitations

Despite these exciting advances, several hurdles remain before any single approach can achieve widespread clinical adoption.

Long-Term Graft Survival

Even with the best current protocols, median islet graft survival is only 5–7 years. Loss of function is multifactorial, involving chronic inflammation, metabolic exhaustion of beta cells, and recurrent autoimmunity in type 1 diabetes patients. Many innovative strategies have only been tested in short-term animal models or with limited follow-up in humans. Durability data are urgently needed. For encapsulation approaches, long-term patency of the membrane and prevention of fibrotic overgrowth beyond 1–2 years remain unproven.

Biocompatibility and Fibrosis

Encapsulation devices, even those made from advanced polymers, can elicit a foreign body response that covers the membrane with fibrotic tissue. This barrier blocks diffusion and starves the islets within weeks to months. Coating devices with antifouling materials like zwitterionic polymers or embedding them with anti-inflammatory agents are active areas of research. Macrophage depletion strategies (e.g., using clodronate liposomes) have shown promise in rodent models but are not yet clinically translatable.

Oxygen Supply

Islets are metabolically active and require substantial oxygen. In the liver, islets receive oxygen from the portal circulation, but oxygen tension is only 20–40 mmHg—well below what is needed for optimal function. Encapsulation devices further restrict oxygen diffusion. Innovative solutions include oxygen-generating biomaterials (e.g., calcium peroxide–embedded scaffolds), direct oxygen refilling ports (as in the Beta-O2 device), and prevascularized implant sites that develop their own blood supply. A recent study used a 3D-printed scaffold containing islets and a sustained-release oxygen source to maintain normoglycemia in diabetic mice for 6 months.

Cost and Scalability

Many of these innovations rely on expensive biologics, gene-editing techniques, or custom-engineered devices. For islet transplantation to become a standard therapy for millions of patients, costs must come down. Automated microfluidics for conformal coating, closed-loop Treg manufacturing, and off-the-shelf cell lines (e.g., stem cell–derived islets) are being developed to address scalability. The recent approval of a stem cell–derived islet therapy (VX-880) has opened the door to potential cost reduction through industrial scale-up.

The Liver Microenvironment

The choice of transplant site remains suboptimal. The portal vein is used for historical and practical reasons, but it exposes islets to low oxygen, high pressure, and gut-derived endotoxins. Alternative sites—omentum, subcutaneous space, the kidney capsule, and even the anterior chamber of the eye—are being evaluated. The omentum, in particular, offers a rich blood supply and easy accessibility for implanted devices. A phase 1 trial of omental implantation of encapsulated islets with an oxygen supply is ongoing.

Future Directions: Combining Strategies for Synergy

The most likely path to success involves combining multiple innovations rather than relying on a single silver bullet. For example, one could envision a protocol where:

  • Stem cell–derived islets (e.g., from induced pluripotent stem cells) are genetically edited to express PD-L1, HLA-E, or CTLA4-Ig and knock out HLA class I.
  • The modified islets are microencapsulated in an alginate variant resistant to fibrosis, with co-encapsulation of IL-10 or a JAK inhibitor microparticle for local immunosuppression.
  • The recipient receives a short course of costimulatory blockade (belatacept) and an infusion of donor-specific CAR-Tregs engineered to home to the graft.
  • The transplant site is the omentum, prevascularized with a biodegradable scaffold that supplies oxygen for the first 4 weeks until neovascularization occurs.

Such a multi-layered approach could reduce immune attack to near-zero while minimizing off-target effects. The Journal of Diabetes Investigation review on combination therapies highlights several ongoing preclinical studies that combine encapsulation with local immunomodulation.

The Role of Stem Cell–Derived Islets

The field is slowly shifting from reliance on cadaveric donor islets to renewable sources provided by stem cell technology. Companies like Vertex and ViaCyte have clinical programs using pluripotent stem cell–derived pancreatic progenitors or beta-like cells. These cells can be genetically engineered prior to transplantation, opening the door to universal donor lines that lack immunogenicity. The first-in-human trials of Vertex’s VX-880 have shown remarkable early results, with patients achieving insulin independence. Combining such cells with a scalable encapsulation system and a short-course immunosuppression regimen could eliminate the two biggest constraints: donor availability and chronic rejection. A second-generation product, VX-264, uses an immune-protective device to avoid immunosuppression entirely.

Advanced Immune Monitoring

An increasingly important area is real-time immune monitoring to detect rejection before it causes irreversible damage. Biomarkers such as donor-specific cell-free DNA, cytokines in the portal blood, and microRNA signatures are being validated. Portable mass spectrometry and microfluidic platforms could one day allow daily patient self-monitoring, triggering early intervention such as boosted immunosuppression or local delivery of anti-inflammatory agents. The Nature Reviews Endocrinology article on islet transplantation biomarkers provides an overview of the latest tools. A new technique using single-cell RNA sequencing of fine-needle aspirates from the graft site can identify rejection signatures days before clinical changes occur.

Artificial Intelligence and Personalized Immunosuppression

Machine learning algorithms are being developed to predict rejection risk based on donor-recipient HLA mismatch, genetic polymorphisms, and early immune monitoring data. These tools could tailor immunosuppression intensity and duration for each patient, reducing over-immunosuppression and associated toxicities. The TITAN trial is evaluating an AI-driven protocol that adjusts tacrolimus dosing based on real-time pharmacogenomic data in kidney transplant recipients; similar approaches are being adapted for islet recipients.

Conclusion

Reducing rejection in islet cell transplantation is not merely a technical goal—it is the key that unlocks the full potential of cellular therapy for diabetes. The innovations described here—targeted immunosuppression, encapsulation, genetic modification, immune tolerance induction, and advanced monitoring—represent a convergence of immunology, materials science, gene editing, and data analytics. Each approach addresses a specific weakness in the current paradigm, and their combination offers a realistic path toward indefinite graft survival without systemic immunosuppression. With ongoing clinical trials and accelerating preclinical successes, the prospect of a durable, rejection-proof islet transplant is closer than ever. The next decade will determine whether these innovative approaches can move from the bench to the bedside, transforming the lives of millions living with diabetes.